Current advances in research and clinical applications of PLGA-based nanotechnology

Abstract

Co-polymer poly(lactic-co-glycolic acid) (PLGA) nanotechnology has been developed for many years and has been approved by the US FDA for the use of drug delivery, diagnostics and other applications of clinical and basic science research, including cardiovascular disease, cancer, vaccine and tissue engineering. This article presents the more recent successes of applying PLGA-based nanotechnologies and tools in these medicine-related applications. It focuses on the possible mechanisms, diagnosis and treatment effects of PLGA preparations and devices. This updated information will benefit to both new and established research scientists and clinical physicians who are interested in the development and application of PLGA nanotechnology as new therapeutic and diagnostic strategies for many diseases.

Keywords::

• cancer
• cardiovascular disease
• diagnosis
• drug delivery
• imaging
• nanoparticle
• nanotechnology
• polylactic-co-glycolic acid
• vaccine

Financial & competing interests disclosure

This work was partially supported by a NIH Grant (EB002436) and by the Michael E DeBakey Department of Surgery, Baylor College of Medicine, and Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.